Decristoforo C - Search Results

1

Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.

Ocak M, Helbok A, von Guggenberg E, Ozsoy Y, Kabasakal L, Kremser L, Decristoforo C. Ocak M, et al. Among authors: decristoforo c. Nucl Med Biol. 2011 Feb;38(2):171-9. doi: 10.1016/j.nucmedbio.2010.07.009. Nucl Med Biol. 2011. PMID: 21315272

2

A simple two-strip method to determine the radiochemical purity of technetium-99m mercaptoacetyltriglycine.

Chen F, Decristoforo C, Rohrbacher B, Riccabona G. Chen F, et al. Among authors: decristoforo c. Eur J Nucl Med. 1993 Apr;20(4):334-8. doi: 10.1007/BF00169810. Eur J Nucl Med. 1993. PMID: 8491226

3

99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution.

Decristoforo C, Mather SJ. Decristoforo C, et al. Nucl Med Biol. 1999 May;26(4):389-96. doi: 10.1016/s0969-8051(98)00118-8. Nucl Med Biol. 1999. PMID: 10382842

4

99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. Decristoforo C, et al. Eur J Nucl Med. 2000 Sep;27(9):1318-25. doi: 10.1007/s002590000289. Eur J Nucl Med. 2000. PMID: 11007513

5

Surfactant protein B labelled with [(99m)Tc(CO)3(H20)3](+) retains biological activity in vitro.

Amann A, Decristoforo C, Ott I, Wenger M, Bader D, Alberto R, Putz G. Amann A, et al. Among authors: decristoforo c. Nucl Med Biol. 2001 Apr;28(3):243-50. doi: 10.1016/s0969-8051(01)00192-5. Nucl Med Biol. 2001. PMID: 11323233

6

The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides.

Decristoforo C, Mather SJ. Decristoforo C, et al. Q J Nucl Med. 2002 Sep;46(3):195-205. Q J Nucl Med. 2002. PMID: 12134136 Review.

7

99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.

Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E, Heute D, Moncayo R. Gabriel M, et al. Among authors: decristoforo c. Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):330-41. doi: 10.1007/s00259-003-1376-x. Epub 2003 Nov 19. Eur J Nucl Med Mol Imaging. 2004. PMID: 14625664 Clinical Trial.

8

99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.

Gabriel M, Decristoforo C, Maina T, Nock B, vonGuggenberg E, Cordopatis P, Moncayo R. Gabriel M, et al. Among authors: decristoforo c. Cancer Biother Radiopharm. 2004 Feb;19(1):73-9. doi: 10.1089/108497804773391702. Cancer Biother Radiopharm. 2004. PMID: 15068614 Clinical Trial.

9

99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.

von Guggenberg E, Behe M, Behr TM, Saurer M, Seppi T, Decristoforo C. von Guggenberg E, et al. Among authors: decristoforo c. Bioconjug Chem. 2004 Jul-Aug;15(4):864-71. doi: 10.1021/bc0300807. Bioconjug Chem. 2004. PMID: 15264875

10

Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-octreotide.

von Guggenberg E, Penz B, Kemmler G, Virgolini I, Decristoforo C. von Guggenberg E, et al. Among authors: decristoforo c. Appl Radiat Isot. 2006 Feb;64(2):194-200. doi: 10.1016/j.apradiso.2005.07.019. Epub 2005 Aug 31. Appl Radiat Isot. 2006. PMID: 16139504

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters